Literature DB >> 19566787

Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma.

Wendy A Henderson1, Ravi Shankar, Jessica M Gill, Kevin H Kim, Marc G Ghany, Melissa Skanderson, Adeel A Butt.   

Abstract

Approximately 3.2 million people in the United States have chronic hepatitis C virus (HCV) infection; the primary cause for adult liver transplantation and a significant burden on healthcare resources. The role of HCV and other risk factors in development of HCC in patients with chronic kidney disease is not well defined. We studied predictors of hepatocellular carcinoma (HCC) in dialysis patients with chronic HCV by analyzing factors associated with its development. Data were extracted from the United States Renal Database System (USRDS) using ICD-9 codes. Variables included were gender, race, duration on dialysis and co-morbidities (alcohol abuse, drug abuse, HIV, hepatitis B, diabetes and/or presence of cirrhosis). Among the 32 806 HCV infected subjects, 262 cases had HCC. HCC was 12 times more likely in subjects with cirrhosis (P < 0.001), three times more likely in subjects with alcohol abuse (P < 0.001), and 1.3 times more likely in subjects with diabetes (P = 0.04). Asians were three times more likely (P < 0.001) to have HCC. Females were less likely to have HCC compared to males (P = 0.002). The likelihood of having HCC increased with age (P =0.001). This population-based study demonstrates that among subjects with HCV on dialysis, those with cirrhosis, Asian race and history of alcohol abuse are at highest risk for development of HCC. Furthermore, these findings indicate links between HCV and HCC which are valuable in case management for identifying; monitoring, and managing dialysis patients with HCC.

Entities:  

Mesh:

Year:  2009        PMID: 19566787      PMCID: PMC2956610          DOI: 10.1111/j.1365-2893.2009.01151.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  24 in total

1.  Hemodialysis paradox: survey on the incidence rate of hepatocellular carcinoma in antihepatitis virus C-antibody-positive chronic hemodialysis patients.

Authors:  H Ishida; T Agishi; I Koyama; T Sawada; T Murakami; K Utsumi; K Tsuji; T Kawase; Y Ishii; I Ishimori; I Kaneko; T Tojimbara; I Nakajima; M Mineshima; S Fuchinoue; T Yoshioka
Journal:  Artif Organs       Date:  2001-01       Impact factor: 3.094

Review 2.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

4.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

5.  Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis.

Authors:  Mindie H Nguyen; Alice S Whittemore; Ruel T Garcia; Saraa A Tawfeek; Jing Ning; Suzanna Lam; Teresa L Wright; Emmet B Keeffe
Journal:  Clin Gastroenterol Hepatol       Date:  2004-09       Impact factor: 11.382

6.  Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members.

Authors:  M T Niu; P J Coleman; M J Alter
Journal:  Am J Kidney Dis       Date:  1993-10       Impact factor: 8.860

Review 7.  Chronic hepatitis B and hepatitis C in Asian Americans.

Authors:  Mindie H Nguyen; Emmet B Keeffe
Journal:  Rev Gastroenterol Disord       Date:  2003

8.  Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.

Authors:  Adeel A Butt; Shawn L Fultz; C Kent Kwoh; David Kelley; Melissa Skanderson; Amy C Justice
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Comorbidities and their impact on mortality in HCV and HCV-HIV-coinfected persons on dialysis.

Authors:  Adeel A Butt; Uzma A Khan; Melissa Skanderson
Journal:  J Clin Gastroenterol       Date:  2008-10       Impact factor: 3.062

10.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  9 in total

1.  APASL consensus statements and management algorithms for hepatitis C virus infection.

Authors:  Masao Omata; Tatsuo Kanda; Ming-Lung Yu; Osamu Yokosuka; Seng-Gee Lim; Wasim Jafri; Ryosuke Tateishi; Saeed S Hamid; Wan-Long Chuang; Anuchit Chutaputti; Lai Wei; Jose Sollano; Shiv Kumar Sarin; Jia-Horng Kao; Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2012-03-01       Impact factor: 9.029

2.  Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients.

Authors:  Farahnaz Joukar; Sepiedeh Besharati; Hasan Mirpour; Fariborz Mansour-Ghanaei
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

3.  Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients.

Authors:  Jer-Ming Chang; Chung-Feng Huang; Szu-Chia Chen; Chia-Yen Dai; Ming-Lun Yeh; Jee-Fu Huang; Hsing-Tao Kuo; Wan-Long Chuang; Ming-Lung Yu; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  Int J Med Sci       Date:  2014-03-08       Impact factor: 3.738

Review 4.  APASL consensus statements and recommendation on treatment of hepatitis C.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-04-29       Impact factor: 6.047

5.  Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Hidenori Toyoda; Toshifumi Tada; Koichi Takaguchi; Kunihiko Tsuji; Ei Itobayashi; Daichi Takizawa; Masashi Hirooka; Yohei Koizumi; Hironori Ochi; Koji Joko; Yoshiyasu Kisaka; Yuko Shimizu; Kazuto Tajiri; Joji Tani; Tatsuya Taniguchi; Akiko Toshimori; Shinichi Fujioka
Journal:  Mol Clin Oncol       Date:  2017-03-10

6.  Higher risk of malignant neoplasms in young adults with end-stage renal disease receiving haemodialysis: A nationwide population-based study.

Authors:  Heng-Chih Pan; Chiao-Yin Sun; I-Wen Wu; Tien-Ling Tsai; Chi-Chin Sun; Chin-Chan Lee
Journal:  Nephrology (Carlton)       Date:  2019-01-30       Impact factor: 2.506

7.  Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study.

Authors:  Fung-Chang Sung; Yi-Ting Yeh; Chih-Hsin Muo; Chih-Cheng Hsu; Wen-Chen Tsai; Yueh-Han Hsu
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

Review 8.  Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.

Authors:  Chen-Hua Liu; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2022-07-25       Impact factor: 9.029

9.  Death Does Matter--Cancer Risk in Patients With End-Stage Renal Disease: A Nationwide Population-Based Study With Competing Risk Analyses.

Authors:  Shih-Feng Weng; Yu-Hsien Chiu; Ren-Long Jan; Yi-Chen Chen; Chih-Chiang Chien; Jhi-Joung Wang; Chin-Chen Chu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.